Literature DB >> 26071761

Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy.

Sabina Boangher1, Sophie Goffette2, Vincent Van Pesch3, Pascal Mespouille2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26071761     DOI： 10.1007/s13760-015-0495-z

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN： 0300-9009            Impact factor:   2.396


× No keyword cloud information.
  3 in total

Review 1.  Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.

Authors:  Meredith C Frederick; Michelle H Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

Review 2.  Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations.

Authors:  Ilya Ayzenberg; Robert Hoepner; Ingo Kleiter
Journal:  Ther Clin Risk Manag       Date:  2016-02-19       Impact factor: 2.423

Review 3.  Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.

Authors:  Giancarlo Comi; Hans-Peter Hartung; Rajesh Bakshi; Ian M Williams; Heinz Wiendl
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.